- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Emerging Insights in Diagnosing Recurrent Prostate Cancer in Men with Low PSA Levels
In a recent video interview, Ashesh Jani, M.D., discussed a subset analysis from the SPOTLIGHT trial that examined the utility of the PET PSMA agent flotufolastat F 18 (Posluma) for detecting prostate cancer recurrence in men with low PSA levels lower than 1 ng/mL.
Ashesh Jani, M.D., said there has been a considerable increase in referred post-prostatectomy patients with lower prostate-specific antigen (PSA) levels, making it increasingly important to have diagnostic tools that can help identify recurrent prostate cancer in this patient population.
In a presentation at the recent American Society for Radiation Oncology (ASTRO) conference, Dr. Jani discussed key research findings from a post-hoc analysis of the phase 3 SPOTLIGHT trial that looked at the use of the positron emission tomography (PET) prostate-specific membrane antigen (PSMA) agent flotufolastat F 18 (Posluma, Blue Earth Diagnostics) for patients with suspected prostate cancer recurrence and PSA levels lower than 1 ng/mL.
In a recent interview, Dr. Jani said he and his colleagues found that use of flotufolastat F 18 detected prostate cancer recurrence in 68 percent of patients with a PSA level less than 1 ng/mL and 64 percent of men with PSA levels lower than 0.5 ng/mL.
“With the advent of molecular imaging and novel radiotracers, we’re able to see the source of PSA at lower PSA levels,” noted Dr. Jani, a professor in the Department of Radiation Oncology at the Emory University School of Medicine and the James C. Kennedy Professor in Prostate Cancer at the Winship Cancer Institute of Emory University.
(Editor’s note: For related content, see “Study: PET/CT Multivariate Model Enhances Accuracy for Diagnosing Prostate Cancer,” “Emerging PET Radiotracer May Offer Multiple Advantages in Detecting Prostate Cancer” and “Could a New PSMA PET Agent Improve Detection of Distant Metastatic Lesions in Patients with Prostate Cancer?”)
The use of flotufolastat F 18 also led to the detection of extrapelvic lesions in 39 percent of patients with PSAs between 0.5 and 1 ng/mL, and 21 percent of men with PSA levels lower than 0.5 ng/mL, according to Dr. Jani.
“There was significant potential for changing management decisions based on this test,” emphasized Dr. Jani.
(Editor’s note: For related content on prostate cancer imaging, click here.)
For more insights from Dr. Jani, watch the video below.
Emerging Perspectives on PSMA PET Radiotracers: An Interview with Kenneth J. Pienta, MD
April 24th 2024In a recent interview, Kenneth J. Pienta, M.D., discussed the impact of piflufolastat F18, current directions in research with other PSMA-targeted radiotracers and future possibilities for the role of PSMA PET in the imaging paradigm for prostate cancer.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.
Could a Deep Learning Model for Mammography Improve Prediction of DCIS and Invasive Breast Cancer?
April 15th 2024Artificial intelligence (AI) assessment of mammography images may significantly enhance the prediction of invasive breast cancer and ductal carcinoma in situ (DCIS) in women with breast cancer, according to new research presented at the Society for Breast Imaging (SBI) conference.
Are Prostate Biopsies Necessary in Patients with Negative or Equivocal MRIs and Low PSA Density?
April 2nd 2024Up to 48 percent of unnecessary prostate biopsies could be eliminated by limiting biopsy to patients with PI-RADS 4 and higher MRI assessments and a prostate-specific antigen density level below 0.15 ng/mL2, according to a new meta-analysis.
